DE3689715D1 - Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden. - Google Patents

Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden.

Info

Publication number
DE3689715D1
DE3689715D1 DE86307926T DE3689715T DE3689715D1 DE 3689715 D1 DE3689715 D1 DE 3689715D1 DE 86307926 T DE86307926 T DE 86307926T DE 3689715 T DE3689715 T DE 3689715T DE 3689715 D1 DE3689715 D1 DE 3689715D1
Authority
DE
Germany
Prior art keywords
oligonucleotides
reagents
methods
vitro synthesis
vitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE86307926T
Other languages
English (en)
Other versions
DE3689715T2 (de
Inventor
Brian Carl Froehler
Mark Douglas Matteucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE3689715D1 publication Critical patent/DE3689715D1/de
Application granted granted Critical
Publication of DE3689715T2 publication Critical patent/DE3689715T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
DE3689715T 1985-10-15 1986-10-14 Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden. Expired - Fee Related DE3689715T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78728085A 1985-10-15 1985-10-15
US06/910,048 US4959463A (en) 1985-10-15 1986-09-19 Intermediates

Publications (2)

Publication Number Publication Date
DE3689715D1 true DE3689715D1 (de) 1994-04-21
DE3689715T2 DE3689715T2 (de) 1994-08-18

Family

ID=27120638

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3689715T Expired - Fee Related DE3689715T2 (de) 1985-10-15 1986-10-14 Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden.

Country Status (4)

Country Link
US (3) US4959463A (de)
EP (1) EP0219342B1 (de)
JP (3) JP2511005B2 (de)
DE (1) DE3689715T2 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362866A (en) * 1983-09-02 1994-11-08 Molecular Biosystems, Inc. Oligonucleotide polymeric support system with an oxidation cleavable link
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US5204456A (en) * 1986-04-08 1993-04-20 Commissariat A L'energie Atomique Derivatives of nucleosides and their use for the synthesis of oligonucleotides
FR2596761B1 (fr) * 1986-04-08 1988-05-20 Commissariat Energie Atomique Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides
US4816571A (en) * 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
US5194599A (en) * 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US6756496B1 (en) 1988-09-23 2004-06-29 Isis Pharmaceuticals, Inc. Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues
US5262530A (en) * 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
GB8902689D0 (en) * 1989-02-07 1989-03-30 Ici Plc Assay method
US5149798A (en) * 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5204455A (en) * 1989-06-15 1993-04-20 Froehler Brian C Monomethoxytrityl protected oligonucleotides bound to a solid support
US6300486B1 (en) * 1989-06-15 2001-10-09 Isis Pharmaceuticals, Inc. Large scale synthesis of oligonucleotides and their associated analogs
US5164491A (en) * 1989-06-15 1992-11-17 Gilead Sciences Large scale synthesis of oligonucleotides and their associated analogs
WO1991006678A1 (en) * 1989-10-26 1991-05-16 Sri International Dna sequencing
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5321131A (en) * 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5214134A (en) * 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5432272A (en) * 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5610274A (en) * 1991-11-20 1997-03-11 Cpg, Inc. Production and use of magnetic porous inorganic materials
US5734020A (en) * 1991-11-20 1998-03-31 Cpg, Inc. Production and use of magnetic porous inorganic materials
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) * 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
EP0616612A4 (de) 1991-12-12 1995-01-11 Gilead Sciences Inc Nukleasestabile und bindungsfähige oligomere und verfahren zu ihrer verwendung.
US5817781A (en) * 1992-06-01 1998-10-06 Gilead Sciences, Inc. Modified internucleoside linkages (II)
US5583211A (en) * 1992-10-29 1996-12-10 Beckman Instruments, Inc. Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides
US6087491A (en) * 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
ES2100051T3 (es) * 1993-01-08 1997-06-01 Hybridon Inc Sintesis de bloques dimeros y su uso en el ensamblaje de oligonucleotidos.
US5476925A (en) * 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
KR960703170A (ko) * 1993-06-23 1996-06-19 알버트 디. 프리센. 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
FR2714061B1 (fr) * 1993-12-16 1996-03-08 Genset Sa Procédé de préparation de polynucléotides sur support solide et appareil permettant sa mise en Óoeuvre.
US5637684A (en) * 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5623068A (en) * 1994-03-07 1997-04-22 Beckman Instruments, Inc. Synthesis of DNA using substituted phenylacetyl-protected nucleotides
US6639061B1 (en) 1999-07-07 2003-10-28 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate oligomers and related compounds
US5514789A (en) * 1994-04-21 1996-05-07 Barrskogen, Inc. Recovery of oligonucleotides by gas phase cleavage
US5763594A (en) * 1994-09-02 1998-06-09 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US5872244A (en) * 1994-09-02 1999-02-16 Andrew C. Hiatt 3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds
US6214987B1 (en) 1994-09-02 2001-04-10 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides
US5990300A (en) * 1994-09-02 1999-11-23 Andrew C. Hiatt Enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
US5808045A (en) * 1994-09-02 1998-09-15 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
US6232465B1 (en) 1994-09-02 2001-05-15 Andrew C. Hiatt Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
US5639875A (en) * 1995-02-01 1997-06-17 Hybridon, Inc. Methods for H-phosphonate syntheis of oligonucleotides using triphosgene
US5683875A (en) * 1995-05-04 1997-11-04 Hewlett-Packard Company Method for detecting a target nucleic acid analyte in a sample
US6140482A (en) * 1995-06-01 2000-10-31 Hybridon, Inc. Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
WO1996039414A1 (en) * 1995-06-01 1996-12-12 Hybridon, Inc. Novel base protecting groups for oligonucleotide synthesis
US6531589B1 (en) 1995-06-01 2003-03-11 Hybridon, Inc. Base protecting groups and synthons for oligonucleotide synthesis
US5962674A (en) * 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
US5955599A (en) * 1995-06-01 1999-09-21 Hybridon, Inc. Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
US5856464A (en) * 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
EP0863910A1 (de) 1995-10-19 1998-09-16 NeXstar Pharmaceuticals, Inc. Verfahren zur herstellung von oligonucleotiden in lösungen
US5705629A (en) * 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
WO1998017675A1 (en) * 1996-10-18 1998-04-30 Hybridon, Inc. Improved methods for h-phosphonate synthesis of mono- and oligonucleotides
US5760209A (en) * 1997-03-03 1998-06-02 Isis Pharmaceuticals, Inc. Protecting group for synthesizing oligonucleotide analogs
US5902881A (en) * 1997-03-03 1999-05-11 Isis Pharmaceuticals, Inc. Reagent useful for synthesizing sulfurized oligonucleotide analogs
ES2131463B1 (es) 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
US6114519A (en) * 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6242591B1 (en) * 1997-10-15 2001-06-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized 2'-substituted oligonucleotides
US6441150B1 (en) * 1997-12-16 2002-08-27 Isis Pharmaceuticals, Inc. Compounds for the Synthesis of Nucleotide or oligonucleotide phosphoramidites
US7273933B1 (en) * 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6965041B1 (en) 1999-03-24 2005-11-15 The United States Of America As Represented By The Department Of Health And Human Services N-acylphosphoramidites and their use in oligonucleotide synthesis
US6932943B1 (en) 2001-01-26 2005-08-23 Third Wave Technologies Nucleic acid synthesizers
US7435390B2 (en) * 2001-01-26 2008-10-14 Third Wave Technologies, Inc. Nucleic acid synthesizers
US20080261220A1 (en) * 2000-11-30 2008-10-23 Third Wave Technologies, Inc. Nucleic Acid Detection Assays
US20030072689A1 (en) * 2001-08-15 2003-04-17 Third Wave Technologies, Inc. Polymer synthesizer
WO2002046205A2 (en) * 2000-12-05 2002-06-13 Avecia Limited Process for the preparation of phosphorothionate oligonucleotides
WO2002081476A1 (en) * 2001-04-06 2002-10-17 Micrologix Biotech, Inc. Thiophosphate nucleic acid-based compounds
WO2003048179A2 (en) 2001-12-03 2003-06-12 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Thermolabile hydroxyl protecting groups and methods of use
CA2475003A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20050009051A1 (en) * 2002-09-27 2005-01-13 Board Of Regents, The University Of Texas Diagnosis of mould infection
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
CA2557841A1 (en) * 2004-02-27 2005-09-09 President And Fellows Of Harvard College Polony fluorescent in situ sequencing beads
EP2471921A1 (de) 2004-05-28 2012-07-04 Asuragen, Inc. Verfahren und Zusammensetzungen mit microRNA
ES2345993T3 (es) 2004-09-14 2010-10-07 The Regents Of The University Of Colorado, A Body Corporate Metodo para el tratamiento con bucindolol basado en direccionamiento genetico.
EP2302054B1 (de) 2004-11-12 2014-07-16 Asuragen, Inc. Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind
WO2006065751A2 (en) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US20090264635A1 (en) 2005-03-25 2009-10-22 Applera Corporation Methods and compositions for depleting abundant rna transcripts
WO2008036765A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
EP2104737B1 (de) 2006-12-08 2013-04-10 Asuragen, INC. Funktionen und ziele von let-7-mikro-rnas
BRPI0906429B1 (pt) 2008-01-10 2021-08-03 Research Development Foundation Método de identificação de uma infecção por e. chaffeensis em um indivíduo, uso de um ou mais polipeptídeo sintético e kit
MX2010008168A (es) 2008-01-25 2011-02-24 P53 Inc Biomarcadores p53.
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US20100047876A1 (en) * 2008-08-08 2010-02-25 President And Fellows Of Harvard College Hierarchical assembly of polynucleotides
AU2009313255B2 (en) 2008-11-07 2014-08-07 Research Development Foundation Compositions and methods for the inhibition of Cripto/GRP78 complex formation and signaling
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
EP2379720B1 (de) 2009-01-20 2016-08-17 Alona Zilberberg Durch den promoter mir-21 angetriebene gezielte krebstherapie
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
WO2011008530A2 (en) 2009-06-29 2011-01-20 Luminex Corporation Chimeric primers with hairpin conformations and methods of using same
CA2771769C (en) 2009-08-28 2019-10-29 Research Development Foundation Urocortin 2 analogs and uses thereof
US9512481B2 (en) 2009-09-11 2016-12-06 The Regents Of The University Of Colorado, A Body Corporate Polymorphisms in the PDE3A gene
EP2515899B1 (de) 2009-12-23 2016-05-25 ARCA biopharma, Inc. Verfahren und zusammensetzungen für herz-kreislauf-erkrankungen und -leiden
WO2011099664A1 (ko) 2010-02-12 2011-08-18 엠앤디(주) Ｈｐｖ 유전자형 진단용 프로브 및 그 분석방법
EP2538943B1 (de) 2010-02-25 2016-03-30 Dana-Farber Cancer Institute, Inc. Braf-mutationen für resistenz gegen braf-inhibitoren
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
WO2011128886A1 (en) 2010-04-12 2011-10-20 Ramot At Tel Aviv University Ltd. A micro-rna for cancer diagnosis, prognosis and therapy
WO2011156588A1 (en) 2010-06-09 2011-12-15 Dana-Farber Cancer Institute, Inc. A mek 1 mutation conferring resistance to raf and mek inhibitors
NZ719520A (en) 2010-07-06 2017-07-28 Int Tech Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
CA2814049C (en) 2010-10-08 2021-07-13 President And Fellows Of Harvard College High-throughput single cell barcoding
ES2629890T3 (es) 2010-11-17 2017-08-16 Interpace Diagnostics, Llc miARN como biomarcadores para distinguir entre neoplasias de tiroides benignas y malignas
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
EP2670849A1 (de) 2011-02-03 2013-12-11 Mirna Therapeutics, Inc. Synthetische mimetika von mir-124
MY165507A (en) 2011-02-03 2018-03-28 Mirna Therapeutics Inc Synthetic mimics of mir-34
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2013037065A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
US10501791B2 (en) 2011-10-14 2019-12-10 President And Fellows Of Harvard College Sequencing by structure assembly
WO2013063519A1 (en) 2011-10-26 2013-05-02 Asuragen, Inc. Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
EP3369818B1 (de) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna zur behandlung von kopf-hals-karzinom
WO2013184754A2 (en) 2012-06-05 2013-12-12 President And Fellows Of Harvard College Spatial sequencing of nucleic acids using dna origami probes
CN104662544B (zh) 2012-07-19 2018-08-03 哈佛大学校长及研究员协会 利用核酸存储信息的方法
EP2897633B1 (de) 2012-09-18 2020-01-01 UTI Limited Partnership Behandlung von schmerzen durch hemmung von usp5-deubiquitinase
US20140100124A1 (en) 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
US9476089B2 (en) 2012-10-18 2016-10-25 President And Fellows Of Harvard College Methods of making oligonucleotide probes
EP2917348A1 (de) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Kombination zur behandlung von erkrankungen oder zuständen im zusammenhang mit melanom oder behandlung von erkrankungen und zuständen im zusammenhang mit aktivierten b-raf-signalweg
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
US10398661B2 (en) 2013-02-28 2019-09-03 The Board Of Regents Of The University Of Texas System Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers
US10138509B2 (en) 2013-03-12 2018-11-27 President And Fellows Of Harvard College Method for generating a three-dimensional nucleic acid containing matrix
EP2970909A4 (de) 2013-03-15 2017-02-15 The University of Chicago Verfahren und zusammensetzungen in zusammenhang mit t-zell aktivität
US10028902B2 (en) 2013-11-08 2018-07-24 Baylor Research Institute Nuclear localization of GLP-1 stimulates myocardial regeneration and reverses heart failure
US11421229B2 (en) 2015-02-20 2022-08-23 Baylor College Of Medicine p63 inactivation for the treatment of heart failure
US20190177391A1 (en) 2016-03-31 2019-06-13 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
US10927379B2 (en) 2016-09-16 2021-02-23 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
US11497762B2 (en) 2017-11-03 2022-11-15 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
CN116585308A (zh) 2018-05-25 2023-08-15 Arca生物制药有限公司 涉及布新洛尔治疗心房颤动的方法和组合物
WO2022097157A2 (en) 2020-11-09 2022-05-12 1E Therapeutics, Ltd. Catalytic sequence based methods of treating or preventing bacterial infections
WO2022144883A2 (en) 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
AU2021411103A1 (en) 2020-12-28 2023-07-13 1E Therapeutics, Ltd. P21 mrna target areas for silencing
EP4320445A1 (de) 2021-04-08 2024-02-14 Joslin Diabetes Center, Inc. Verfahren zur diagnose und vorhersage von nierenabbau
WO2024015766A1 (en) 2022-07-12 2024-01-18 Topogene Inc. Scalable, submicron-resolution replication of dna arrays

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) * 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
FR2476092A1 (fr) * 1980-02-20 1981-08-21 Commissariat Energie Atomique Procede de synthese de polynucleotides
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
JP2547714B2 (ja) * 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
IL69196A0 (en) * 1982-08-20 1983-11-30 Genex Corp Solid phase synthesis of oligonucleotides
DE3239888A1 (de) * 1982-10-28 1984-05-03 Hubert Prof. Dr. 2000 Hamburg Köster Verfahren zur herstellung von oligonucleosidphosphonaten
US4547569A (en) * 1982-11-24 1985-10-15 The United States Of America As Represented By The Department Of Health And Human Services Intercalating agents specifying nucleotides
FR2540122B1 (fr) * 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
DE3329892A1 (de) * 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg Verfahren zur herstellung von oligonucleotiden
DE3332068A1 (de) * 1983-09-06 1985-03-21 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von nukleosidalkyl-, aralkyl- und arylphosphoniten und -phosphonaten
US4507433A (en) * 1983-10-07 1985-03-26 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates
JPS60197698A (ja) * 1983-12-20 1985-10-07 カリフオルニア・インステイテユ−ト・オブ・テクノロジ− アミノ誘導化されたオリゴヌクレオチドの合成
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates

Also Published As

Publication number Publication date
US5264566A (en) 1993-11-23
JP2511005B2 (ja) 1996-06-26
JPH0812698A (ja) 1996-01-16
US5548076A (en) 1996-08-20
JP2705914B2 (ja) 1998-01-28
JP2705913B2 (ja) 1998-01-28
JPS62116593A (ja) 1987-05-28
JPH0812697A (ja) 1996-01-16
EP0219342A2 (de) 1987-04-22
EP0219342A3 (en) 1987-12-16
US4959463A (en) 1990-09-25
EP0219342B1 (de) 1994-03-16
DE3689715T2 (de) 1994-08-18

Similar Documents

Publication Publication Date Title
DE3689715D1 (de) Verfahren und Reagenzien für die In-vitro-Synthese von Oligonukleotiden.
DE69009545D1 (de) Verfahren zur Sprachanalyse und -synthese.
DE3688093T2 (de) Durchsichtiger Gegenstand und Verfahren zu seiner Herstellung.
DE3673548D1 (de) Hydrokonversionskatalysator und verfahren.
DE3780560D1 (de) Fuehler und verfahren zu dessen herstellung.
DE3681992D1 (de) Ruehrwerk zur benutzung in biochemischen reaktionen.
DE3677044D1 (de) Verfahren zur herstellung von emulsionen und die so erhaltenen emulsionen.
DE68924498T2 (de) Verfahren für die Herstellung von Perfluoroxyethylen- und Perfluoroxypropyleneinheiten enthaltenden Perfluoropolyäthern.
DE3780029T2 (de) Farblose transparente polyimid-formkoerper und verfahren zu deren herstellung.
DE3650264T2 (de) Aluminiumnitridsinterkörper und Verfahren zu seiner Herstellung.
DE3751691T2 (de) Rotierende Angioplastiesysteme für die klinische Anwendung
DE3777141D1 (de) Mikrokapseln und verfahren zur herstelllung.
DE3882075T2 (de) Verfahren zur Ammoxidation und Katalysatorzusammensetzung dafür.
DE68908712T2 (de) Edelmetall enthaltende katalysatoren und verfahren zur herstellung.
DE69132830T2 (de) Verfahren und Reagentien für die Identifikation von Bakterien
NZ215453A (en) Method of synthesis of oligonucleotides and assays
DE3578454D1 (de) Klinisches analysesystem und verfahren.
DE3873836T2 (de) Aluminiumborat-whisker und verfahren zu ihrer herstellung.
DE3788205D1 (de) Etikett und Verfahren zu seiner Herstellung.
BR8800586A (pt) Catalisador e processo de preparacao do mesmo
DE69021465D1 (de) Verfahren und Form für kaschierte Paneele.
FI884884A (fi) Katalyyttinen vahanpoistomenetelmä
DE3786978T2 (de) Verfahren für die Zuführung von Kulturmedium und Kultursystem.
DE69013726D1 (de) Verbessertes Verfahren für die Herstellung von o-Carboxypyridyl- und o-Carboxychinolylimidazolinonen.
DE3675608D1 (de) Leuchtstoff und verfahren zu seiner herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee